LAS VEGAS, Nov. 16, 2017 /Weed Wire/ – November 16, 2017 – Freedom Leaf, Inc. (OTCQB: FRLF), “The Marijuana Legalization Company®,” announced a research report on the company is now available for review.
Report Highlights Hempology Product Line
– Penetration into Latin America Market
– Upcoming Acquisition in Spain of Green Market Europe, S. L.
– NuAxon CO2 Extractor Sales
– Appointment of Mr. Pelosi, Jr. as Chairman of the Board
– Improved Revenue and Compliance Outlook
In the report, Ludlow Research made note of FRLF pending launch of their Hempology consumer line, appointment of Mr. Pelosi Jr. as the new Chairman of the Board of Directors, and potential expansion into Latin American cannabis market through with the recent acquisition of LaMarihuana.com
Based on the appointment of Mr. Pelosi as the new Chairman of the company, and their ongoing operations such as Hempology, Green Market Europe S. L., NuAxon CO2 Extractor sales, and penetration into the Latin American market, along with expectation of the projected sales through June, 2017, Ludlow Research has upgraded its research opinion on Freedom Leaf, Inc. (OTCQB: FRLF).
To download the full report, risks, and disclosures on this company please visit http://www.ludlowresearch.com/reports.html
About Ludlow Research
Ludlow Research is a New York based equity research firm that focuses on providing research coverage and investor awareness services to emerging small-cap companies. For over 14 years we have worked to provide our readers with a simple way of evaluating the current and potential value of small-cap companies, while garnering these clients greater market awareness to new investors. For more information on us please visit www.ludlowresearch.com
About Freedom Leaf
Freedom Leaf, Inc., The Marijuana Legalization Company®, is a fully reporting and audited, publicly traded company trading under the symbol (OTCQB: FRLF). Freedom Leaf, Inc. is a leading go-to resource in the cannabis, medical marijuana, and industrial hemp industry. It is involved in mergers and acquisitions and business consulting in the marijuana industry, including incubation/acceleration and spin offs of new marijuana/hemp related companies.
Freedom Leaf, Inc.’s flagship publication is Freedom Leaf Magazine, “The Good News in Marijuana Reform.” The company produces a portfolio of news, print and digital multi-media verticals, websites, blogs and web advertising, for the ever-changing emerging cannabis, medical marijuana and industrial hemp industry.
Freedom Leaf, Inc. does not handle, grow, sell, or dispense marijuana. All of our European activities are in full compliance with relevant EU laws.
Corporate Website and Investor Relations www.FreedomLeafInc.com
Safe Harbor Statement
Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, including any financial projections above, generally can be identified by phrases such as Freedom Leaf, Inc. or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” “projections” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company’s products and services, changes in relationships with third parties, and other factors described in the Company’s most recent periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K dated June 30, 2017 and quarterly reports on Form 10-Q.
Raymond P Medieros
PR and Business Development Director